NSEChange in Director(s)13 Jul 2026 · 13 Jul 2026, 05:37 pm

Change in Director(s)

Sun Pharma Advanced Research Company Limited · SPARC

✦ AI SummaryMgmt Change

Sun Pharma Advanced Research Company Limited has informed the Exchange regarding Change in Director(s) of the company. Dr. Rajamannar Thennati retires from the Board of Directors upon completion of his term, and Mr. Anil Raghavan is appointed as Managing Director and Chief Executive Officer with effect from August 11, 2026.

Analysis Scores

Earnings Impact5/10
Growth Catalyst6/10
Governance Concern2/10
Regulatory Risk1/10
Balance Sheet Risk4/10
Liquidity Impact8/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Sun Pharma Advanced Research Company Limited has informed the Exchange regarding Change in Director(s) of the company.

Attachments (1)

📄

SPARC_13072026173744_Reg30Intimation13072026.pdf

pdf

Download →
View document text
SPARC/Sec/SE/2026-27/20 July 13, 2026 National Stock Exchange of India Ltd., BSE Limited, Exchange Plaza, 5th Floor, Market Operations Dept. Plot No. C/1, G Block, P. J. Towers, Bandra Kurla Complex, Dalal Street, Bandra (East), Mumbai – 400 051. Mumbai - 400 001. Scrip Symbol: SPARC Scrip Code: 532872 Dear Sir/Madam, Sub: Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) Pursuant to Regulation 30 read with Schedule III of SEBI Listing Regulations, we wish to inform you, the Board of Directors of the Company has considered and approved the following: 1. Dr. Rajamannar Thennati (DIN: 001415412) retires from the Board of Directors of the Company upon completion of his term as a Director at the ensuing 21st Annual General Meeting i.e., August 10, 2026. 2. Appointment of Mr. Anil Raghavan (DIN: 03548731), Chief Executive Officer (CEO) of the Company as Managing Director and Chief Executive Officer of the Company with effect from August 11, 2026 and liable to retire by rotation, subject to the approval of members at the ensuing 21st Annual General Meeting of the Company. Mr. Anil Raghavan is not related to any other director of the Company and is not debarred from holding the office of director by any SEBI order or any other authority Details required under Regulation 30 read with Para A of Schedule III (Part A) of SEBI Listing Regulations, along with the additional details required pursuant to SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, are enclosed herewith as Annexure - A. You are requested to take the above information on record. For Sun Pharma Advanced Research Company Limited Kajal Damania Company Secretary and Compliance Officer Encl: As above Annexure A Disclosures required under Regulation 30 read with Para A of Schedule Ill (Part A) of SEBI Listing Regulations, along with the additional details required under the SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024. Sr. Particulars Details of Senior Management Personnel No Mr. Anil Raghavan Dr. Rajamannar Thennati 1 Reason for change viz. Appointment Retirement appointment, re- appointment, resignation, removal, death or otherwise 2 Date of appointment/re- August 11, 2026 August 10, 2026 appointment/ cessation (as applicable) & term of appointment/re- appointment 3 Brief profile (in case of Mr. Anil Raghavan currently Not Applicable appointment) serves as the Chief Executive Officer of Sun Pharma Advanced Research Company Limited (SPARC). Anil is responsible for developing and executing strategies to realize SPARC’s vision of becoming a Global Pharmaceutical Leader with a portfolio of innovative solutions. He operates from SPARC’s Mumbai office. Mr. Anil also serves as a mentor of an early stage Machine Learning company, AIRAMATRIX Private Limited which focuses on the application of high content image processing and deep learning to transform drug development and clinical practice. Anil spent a decade consulting with leading firms such as Arthur Andersen, KPMG and Cambridge Technology Partners before joining Quintiles. He helped the leadership teams of several companies in developing and evaluating business strategy, and improving business performance. Anil served customers in varied segments like Media and Entertainment, Telecommunications, Health Care services, and Technology/Outsourcing. Anil substantially contributed to developing consulting solutions for the emerging Information Technology and Business Process Outsourcing industries. Anil is an Industrial Engineer with a deep interest in evolving science and technologies in pharmaceutical R&D and health care delivery segments. An active speaker at events, he has participated in several industry sector studies, working with business lobbies and industry associations to highlight sectoral opportunities and challenges. 4 Disclosure of Relationship Mr. Anil Raghavan is not Not Applicable between Directors (in case related to any director of the of appointment of a Company. Director) For Sun Pharma Advanced Research Company Limited Kajal Damania Company Secretary and Compliance Officer